SCHEMBL6079524

SCHEMBL6079524

Cc1c(C(=O)O)nc2c(N)cc(N)cc2c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 3/20 0.34
RAB9A P51151 2/20 0.34
GPR35 Q9HC97 2/20 0.33
LDHA P00338 1/20 0.32
LDHB P07195 1/20 0.32
ALDH1A1 P00352 3/20 0.30
LMNA P02545 2/20 0.30
GAA P10253 2/20 0.30
NPC1 O15118 1/20 0.30
MITF O75030 1/20 0.30
TP53 P04637 1/20 0.30
TSHR P16473 1/20 0.30
AGTR1 P30556 1/20 0.30
HTT P42858 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080260 0.88 KDM4E (0.34) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6081107 0.88 KDM4E (0.41) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6080024 0.85 CYP3A4 (0.38) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6079736 0.85 DHODH (0.38) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6081157 0.83 GPR35 (0.43) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6080356 0.82 PIN1 (0.36) TDP1KDM4EMAPTRAB9ALDHA
SCHEMBL6080431 0.82 DHODH (0.40) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL6080252 0.79 P2RX3 (0.45) KDM4EMEN1KMT2ALDHALDHB
SCHEMBL6080240 0.79 MAPT (0.40) TDP1KDM4EMEN1KMT2AMAPT
SCHEMBL6080402 0.79 PARP1 (0.44) TDP1KDM4EMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL TDP1 2264/4885KDM4E 1006/4885MEN1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.